KAF156 (Ganaplacide) is a drug in development by Novartis for the purpose of treating malaria. It belongs to the class of the imidazolopiperazines.[1][2] It has shown activity against the _Plasmodium falciparum_ and _Plasmodium vivax_ forms of the malaria parasite.[3]
